Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Psittimune APV (Canada)

This page contains information on Psittimune APV for veterinary use.
The information provided typically includes the following:
  • Psittimune APV Indications
  • Warnings and cautions for Psittimune APV
  • Direction and dosage information for Psittimune APV

Psittimune APV

This treatment applies to the following species:
Company: Ceva Animal Health


Killed Virus

PRODUCT DESCRIPTION: Avian Polyomavirus Vaccine is an inactivated viral vaccine prepared from an antigenic isolate of avian polyomavirus. The vaccine contains a virus that is carefully inactivated (killed) to maintain its antigenicity and an adjuvant for enhanced response to vaccination.

Because the polyomavirus in this vaccine is killed, there is no risk of causing polyomavirus infection with use of the vaccine. However, if a bird has recently been infected with polyomavirus but is not yet exhibiting clinical signs, vaccination will not prevent the progression of disease.

DISEASE DESCRIPTION: Polyomavirus infection is one of the leading causes of death in young psittacine birds. Infections in young birds are usually rapidly fatal. Adult birds are also susceptible to polyomavirus infection, and although they seldom suffer clinical illness, they are the source of amplification of polyomavirus within an aviary leading to exposure of neonates in the nursery.

In the budgerigar, the disease is called budgerigar fledgling disease. Clinical signs in acute infections may include abdominal distention, hemorrhage under the skin, reduced formation of down and contour feathers, and neurological signs characterized by ataxia and tremors of the head and neck. Birds that survive infection may exhibit feather abnormalities characterized by dystrophic primary and tail feathers, lack of downfeathers, and lack of filoplumes on the head and neck.

In nonbudgerigar psittacine birds peracute death with no premonitory signs is the most common clinical finding. Acute infection is characterized by death following a period of clinical changes that include depression, anorexia, delayed crop emptying, regurgitation, diarrhea, dehydration, bleeding under the skin, and polyuria. Birds that survive several days after the onset of clinical signs can develop yellowish urates indicative of liver damage. Chronic disease progression typified by weight loss, intermittent anorexia, polyuria, poor feather development, and recurrent bacterial and fungal infections have also been described. In latently infected breeder birds, the virus has been shown to cause decreased egg hatchability, embryonic death, and increased mortality.

INDICATIONS FOR USE: The vaccine is intended for use as an aid in the prevention of avian polyomavirus infection in psittacine birds. Only healthy birds should be vaccinated. Birds weighing 200 grams or greater should receive a 0.5ml dose and birds weighing less than 200 grams should receive a 0.2ml dose. Young birds should not be initially vaccinated before 5 weeks of age. To complete primary immunization a second dose must be given at two to three weeks following the initial vaccination. Annual revaccination is recommended. Susceptible breeders should be vaccinated prior to the laying season. Product performance has been evaluated in selected but not all psittacine species.

ADMINISTRATION: The vaccine should be warmed to room temperature (72°-75°F) before use. It is essential to shake the vaccine before and during use since the vaccine quickly settles. Shake the bottle of vaccine well before removing each dose with a syringe and needle.

Using aseptic technique, the vaccine should be subcutaneously administered with a 26 gauge needle at the caudal end of the breast muscle avoiding the keel. The direction may be toward or away from the head depending on personal preference. Care should be taken not to inject the vaccine into the muscle tissue or internal organs or intradermally. Administer the second vaccination on the contralateral side two to three weeks later.


This vaccine contains gentamicin and amphotericin B as preservatives. A transient loss of appetite (1-3 days) may be seen following the use of this product. The vaccine may cause post-vaccination tissue reactions including discoloration or thickening of the skin or granuloma formation at the site of injection. Certain individual birds may be more sensitive to these types of reactions. Changes should resolve without treatment within 6-8 weeks later. Reactions may also be aggravated by improper vaccination technique. Further complications may result from the stress and handling of birds associated with the vaccination procedure.

NOTICE: Use entire contents when first opened. Store in the dark at 35° to 45°F (2°-7°C). Do not freeze.

PATENT No. 5747045


Manufactured By: BIOMUNE CO., Lenexa, KS 66215 USA

Phone: (913) 894-0230

U.S. Vet Lic. No. 368

Distributed By: Ceva Animal Health, Guelph, Ontario N1K 1E8


10 Doses (5mL)

628, 629

CPN: 12210970

Telephone:   519-650-9570
Toll-Free:   800-510-8864
Fax:   519-650-9576
Every effort has been made to ensure the accuracy of the Psittimune APV information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2020 Animalytix LLC. Updated: 2020-10-21